Serial Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer to Predict the Therapeutic Response

Serial Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer to Predict the Therapeutic Response

Early biomarkers of therapeutic responses can help optimize the treatment of metastatic colorectal cancers (mCRC). In this prospective exploratory study, we examined serial changes of plasma-circulating tumor DNA (ctDNA) in 41 mCRC patients receiving first-line chemotherapies and tested its associat...

Full description

Bibliographic Details
Main Authors:	Ning Jia, Zhao Sun, Xin Gao, Yuejuan Cheng, Yanping Zhou, Chunying Shen, Wei Chen, Xueliang Wang, Rong Shi, Nan Li, Jianfeng Zhou, Chunmei Bai
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2019-05-01
Series:	Frontiers in Genetics
Subjects:	liquid biopsy circulating tumor DNA metastatic colorectal cancer therapeutic response biomarker
Online Access:	https://www.frontiersin.org/article/10.3389/fgene.2019.00470/full

Similar Items

Association of emergence of new mutations in circulating tumuor DNA during chemotherapy with clinical outcome in metastatic colorectal cancer
by: Ning Jia, et al.
Published: (2021-07-01)

Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial
by: François-Clément Bidard, et al.
Published: (2019-05-01)

Circulating Methylated DNA to Monitor the Dynamics of RAS Mutation Clearance in Plasma from Metastatic Colorectal Cancer Patients
by: Chiara Nicolazzo, et al.
Published: (2020-12-01)

Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma
by: C. B. Thomsen, et al.
Published: (2018-03-01)

High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib
by: Alessio Amatu, et al.
Published: (2019-07-01)

Clinical utility of comprehensive circulating tumor DNA genotyping compared with standard of care tissue testing in patients with newly diagnosed metastatic colorectal cancer
by: Alba, E., et al.
Published: (2022)

Clinical Implication of Liquid Biopsy in Colorectal Cancer Patients Treated with Metastasectomy
by: Soohyeon Lee, et al.
Published: (2021-05-01)

Early detection of poor outcome in patients with metastatic colorectal cancer: tumor kinetics evaluated by circulating tumor cells
by: Souza e Silva V, et al.
Published: (2016-12-01)

KRAS Mutational Regression Is Associated With Oligo-Metastatic Status and Good Prognosis in Metastatic Colorectal Cancer
by: Alessandro Ottaiano, et al.
Published: (2021-03-01)

Clinical Perspectives on Liquid Biopsy in Metastatic Colorectal Cancer
by: Wei Gao, et al.
Published: (2021-01-01)

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS‐mutant metastatic colorectal cancer
by: Elena Elez, et al.
Published: (2019-09-01)

REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer
by: Hiromichi Nakajima, et al.
Published: (2021-06-01)

Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol
by: Shang-Hung Chen, et al.
Published: (2019-06-01)

Clinical Utility of Plasma KRAS, NRAS and BRAF Mutational Analysis with Real Time PCR in Metastatic Colorectal Cancer Patients—The Importance of Tissue/Plasma Discordant Cases
by: Vincenzo Formica, et al.
Published: (2021-12-01)

Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer
by: Eleonora Lai, et al.
Published: (2020-05-01)

Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients
by: Mayte Delgado-Ureña, et al.
Published: (2018-09-01)

SATB2 is a Promising Biomarker for Identifying a Colorectal Origin for Liver Metastatic Adenocarcinomas
by: Yi-Jun Zhang, et al.
Published: (2018-02-01)

Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients
by: Xiaojing Xu, et al.
Published: (2020-10-01)

Plasma-Based Measurements of Tumor Heterogeneity Correlate with Clinical Outcomes in Metastatic Colorectal Cancer
by: Bendell, J.C, et al.
Published: (2022)

Prognostic and clinicopathological significance of circulating tumor cells detected by RT-PCR in non-metastatic colorectal cancer: a meta-analysis and systematic review
by: Chaogang Yang, et al.
Published: (2017-11-01)

A Systematic Review of the Use of Circulating Cell-Free DNA Dynamics to Monitor Response to Treatment in Metastatic Breast Cancer Patients
by: Elisabeth M. Jongbloed, et al.
Published: (2021-04-01)

Baseline and Kinetic Circulating Tumor Cell Counts Are Prognostic Factors in a Prospective Study of Metastatic Colorectal Cancer
by: Virgílio Souza e Silva, et al.
Published: (2021-03-01)

Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer
by: Prashanth Rawla, et al.
Published: (2019-07-01)

Circulating microRNAs as Promising Biomarkers in Colorectal Cancer
by: Óscar Rapado-González, et al.
Published: (2019-06-01)

Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer
by: Cristina Raimondi, et al.
Published: (2019-01-01)

Rapid response of stage IV colorectal cancer with APC/TP53/KRAS mutations to FOLFIRI and Bevacizumab combination chemotherapy: a case report of use of liquid biopsy
by: Alexander Hendricks, et al.
Published: (2020-01-01)

CLINICAL EXPERIENCE OF COMBINED AVASTIN THERAPY IN METASTATIC COLORECTAL CANCER
by: V. A. Ekimov
Published: (2015-02-01)

Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy
by: Teofila Seremet, et al.
Published: (2019-09-01)

Expert consensus on maintenance treatment for metastatic colorectal cancer in China
by: Rui-Hua Xu, et al.
Published: (2016-01-01)

Clinical significance of peripheral circulating tumor cell counts in colorectal polyps and non-metastatic colorectal cancer
by: Chengguang Yang, et al.
Published: (2018-01-01)

High Concordance of Genomic Profiles between Primary and Metastatic Colorectal Cancer
by: Seung Eun Lee, et al.
Published: (2021-05-01)

CLINICAL EXPERIENCE OF PROLONGED BEVACIZUMAB THERAPY IN METASTATIC COLORECTAL CANCER
by: I. S. Bulavina, et al.
Published: (2015-02-01)

CLINICAL EXPERIENCE OF PROLONGED AVASTIN THERAPY IN METASTATIC COLORECTAL CANCER
by: A. F. Saidullaeva
Published: (2015-02-01)

Using of multi-kinase inhibitor regorafenib for metastatic colorectal cancer
by: O I Kit, et al.
Published: (2017-06-01)

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial
by: William Jacot, et al.
Published: (2019-11-01)

The role of regorafenib in the treatment of metastatic colorectal cancer
by: A A Tryakin
Published: (2016-06-01)

Circulating Tumor DNA as a Novel Biomarker Optimizing Chemotherapy for Colorectal Cancer
by: Hiroki Osumi, et al.
Published: (2020-06-01)

OXALIPLATIN/5-FLUOROURACIL/LEUCOVORIN IN THE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER
by: Deyan N. Davidov
Published: (2013-12-01)

Highly Correlated Recurrence Prognosis in Patients with Metastatic Colorectal Cancer by Synergistic Consideration of Circulating Tumor Cells/Microemboli and Tumor Markers CEA/CA19-9
by: Hsueh-Yao Chu, et al.
Published: (2021-05-01)

The importance of circulating tumor products as „liquid biopsies” in colorectal cancer
by: Alina Miscoci, et al.
Published: (2018-04-01)